~~<i id='62FBCEAEFA'><strike id='62FBCEAEFA'><tt id='62FBCEAEFA'><pre id='62FBCEAEFA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

WSS

Notifications
- Wikipedia
Trump demands the U.S. pay no more for drugs than other countries … again
log on

hotspot

focus

author：leisure time 2025-09-27 04:26:09 - browse：49244

It’s that time of the year again when I recognize the Best Biopharma CEO of the year.

This year’s selection is so deservingly obvious that I won’t fabricate suspense by starting with an honor roll of runners-up. More on those high-achieving folks later. Let’s get right to the main course: David Ricks of Eli Lillyis the runaway, rock star, who-else-could-it-be Best Biopharma CEO of 2023.

What an incredible year it’s been for Ricks and the Lilly executive team who helped him achieve so much. My colleague Matt Herper wrote earlier this year about the “dynamic duo” of Ricks and Chief Scientific Officer Dan Skovronsky.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： IVF doctors demand details after CooperSurgical lawsuit

explore

focus

explore

knowledge

explore

SpencerPlatt/GettyImagesWhatmakesforgoodpublichealthguidance?That’stheconversationIwashavingwithacol

WSS

Covid hospitalizations on the rise, Humana says

First over

AstraZeneca chief proposes a novel edit to the drug pricing bill

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Crinetics acromegaly drug succeeds in late

First over

hotspot

focus

explore

George Santos makes 1st court appearance after pleading not guilty to 13 counts

$1 billion proposal to grow Boston, Massachusetts biotech

At least 13 dead in Texas as scorching temps continue

NIH nominee Bertagnolli will get October confirmation hearing

At least 13 dead in Texas as scorching temps continue

Why Talkspace is targeting Medicare, a tricky market

Alkermes shareholders re

The untold story of TV’s first prescription drug ad

DIEP, the 'gold standard' of breast reconstruction, is under threat

A new House health package & hospitals’ new site

focus

IVF doctors demand details after CooperSurgical lawsuit

Readout Newsletter: BridgeBio, Akero, and human embryo models

Illumina names Agilent executive as new CEO

The (many) problems with a new study criticizing cancer screening

State of the Union pitch: Bigger Medicare drug price negotiations

A new approach to psychiatric drug development

explore

knowledge

explore

explore